RHYTHM PHARMACEUTICALS, INC.

Pharmaceutical Preparations

RYTM Pharmaceuticals & Biotechnology People in Pharmaceuticals & Biotechnology SEC CIK 0001649904 ↗

Computed from SEC EDGAR filings and closing prices — not copied from any wealth ranking. Dataset . How we calculate this.

Market capitalisation
$7.18B
68,852,082 shares Covers every share class this company has on file.
Insiders on file
12
people who have filed Form 3, 4 or 5 naming this issuer
Value of insider-held stock
$54.71M
from the holdings reported on Forms 3/4/5; this figure has no separate as-of date on file
Insider-held share of market cap
0.76%
insider-held value divided by market capitalisation

What RHYTHM PHARMACEUTICALS, INC. reports

Revenue and net income below are for fiscal period FY2025, the period label carried by this company’s own annual XBRL filings to the SEC. Fiscal years do not line up between companies — one company’s FY2026 can cover much the same months as another’s FY2025 — so compare the periods, not just the numbers.

Revenue
$189.76M
FY2025 annual revenue, from this company’s own annual XBRL filings to the SEC
Net income
-$196.5K
FY2025 a loss for the period, from this company’s own annual XBRL filings to the SEC
Employees
414
Yahoo Finance
Where the employee count comes from

Headcount comes from Yahoo Finance, not from a filing. The date beside it is the day we retrieved the figure — it is not the date the company counted its staff, and Yahoo does not publish that date. Unlike the SEC filings behind the other figures on this page, this one carries no open licence, so we publish the number and nothing else from that source.

Insiders at RHYTHM PHARMACEUTICALS, INC.

Shares is what each person last reported holding here.

Everyone below has filed at least one insider report against this company.

Value is that share count priced at the same closing price used everywhere else on this site. A row priced from only some of a person’s securities says so — we do not quietly present a partial sum as a complete one.

Rows are grouped by the role each person reports.

The role comes from the relationship boxes a person ticks on their own insider filings — officer, director, ten per cent owner — not from anything we infer. Somebody who is both an officer and a director appears once, in the combined group, so the row count still matches the figure at the top of this page. Where no filing states a role we say so instead of guessing one.

People who file insider reports against RHYTHM PHARMACEUTICALS, INC..
Insider Reported role Shares Value Last action
Officers 5
Hunter C Smith CFO 116,611 $11.98M S Open-market sale Aug 31, 2026 position reported
Yann Mazabraud EVP 53,155 $5.46M S Open-market sale Aug 12, 2026 position reported
Pamela J Cramer Other Executive 29,376 $3.02M F Shares withheld for taxes Feb 1, 2026 position reported
Jennifer Kayden Lee EVP 19,233 $1.98M S Open-market sale Aug 13, 2026 position reported
Joseph Shulman CTO 18,970 $1.95M S Open-market sale Aug 13, 2026 position reported
Officers who also sit on the board 4
David P Meeker CEO 239,016 $24.56M M Option exercise or conversion Feb 1, 2026 position reported
Camille L Bedrosian Other Executive 7,000 $719.2K M Option exercise or conversion Jun 18, 2025 position reported
Jennifer L. Good Jennifer L. Good CEO 7,000 $719.2K M Option exercise or conversion Jun 23, 2026 position reported
Stuart A Arbuckle COO 7,000 $719.2K M Option exercise or conversion Jun 23, 2026 position reported
Directors 3
Edward T Mathers Board Member 21,168 $2.17M J Other acquisition or disposition Mar 12, 2026 position reported
David W. J. McGirr Board Member 7,000 $719.2K M Option exercise or conversion Jun 23, 2026 position reported
Lynn A. Tetrault Board Member 7,000 $719.2K M Option exercise or conversion Jun 23, 2026 position reported

Events from filings

Detected automatically in the filings linked below. Each headline is built from the numbers in those filings, not written by a model. Newest first; events older than 45 days stay listed and are marked as older.

Hunter C Smith sold 62,774 RHYTHM PHARMACEUTICALS, INC. (RYTM) shares for $6,619,896 on Aug 31, 2026

Large trade for this person

Flagged because this trade was large compared with this person’s own earlier open-market trades in the same currency — not because it is large in absolute terms. A trade that is routine for one insider can be flagged for another.

Hunter C Smith sold 62,774 RHYTHM PHARMACEUTICALS, INC. (RYTM) shares for $6,619,896 on Aug 31, 2026
Date Insider Transaction Shares Price Value Filing
Aug 31, 2026 Hunter C Smith S Open-market sale 23,072 held after: 153,726 $104.59 $2,413,100 SEC filing ↗
Aug 31, 2026 Hunter C Smith S Open-market sale 11,514 held after: 142,212 $105.37 $1,213,230 SEC filing ↗
Aug 31, 2026 Hunter C Smith S Open-market sale 28,188 held after: 114,024 $106.20 $2,993,566 SEC filing ↗

Total of the rows above: $6,619,896, in the currency the filings report.

Source: SEC EDGAR (United States); every row links to where it was published. Event computed Sep 14, 2026.

Jennifer Kayden Lee sold 75,834 RHYTHM PHARMACEUTICALS, INC. (RYTM) shares for $8,901,395 on Aug 13, 2026

Large trade for this person

Flagged because this trade was large compared with this person’s own earlier open-market trades in the same currency — not because it is large in absolute terms. A trade that is routine for one insider can be flagged for another.

Jennifer Kayden Lee sold 75,834 RHYTHM PHARMACEUTICALS, INC. (RYTM) shares for $8,901,395 on Aug 13, 2026
Date Insider Transaction Shares Price Value Filing
Aug 13, 2026 Jennifer Kayden Lee S Open-market sale 75,834 held after: 0 $117.38 $8,901,395 SEC filing ↗

Source: SEC EDGAR (United States); every row links to where it was published. Event computed Sep 14, 2026.

Lynn A. Tetrault sold 37,000 RHYTHM PHARMACEUTICALS, INC. (RYTM) shares for $3,711,840 on Jun 22, 2026

Large trade for this person

Flagged because this trade was large compared with this person’s own earlier open-market trades in the same currency — not because it is large in absolute terms. A trade that is routine for one insider can be flagged for another.

Lynn A. Tetrault sold 37,000 RHYTHM PHARMACEUTICALS, INC. (RYTM) shares for $3,711,840 on Jun 22, 2026
Date Insider Transaction Shares Price Value Filing
Jun 22, 2026 Lynn A. Tetrault S Open-market sale 37,000 held after: 7,000 $100.32 $3,711,840 SEC filing ↗

Source: SEC EDGAR (United States); every row links to where it was published. Event computed Sep 14, 2026.

Joseph Shulman sold 16,781 RHYTHM PHARMACEUTICALS, INC. (RYTM) shares for $1,767,039 on Sep 2, 2025

Large trade for this person

Flagged because this trade was large compared with this person’s own earlier open-market trades in the same currency — not because it is large in absolute terms. A trade that is routine for one insider can be flagged for another.

Joseph Shulman sold 16,781 RHYTHM PHARMACEUTICALS, INC. (RYTM) shares for $1,767,039 on Sep 2, 2025
Date Insider Transaction Shares Price Value Filing
Sep 2, 2025 Joseph Shulman S Open-market sale 16,781 held after: 8,509 $105.30 $1,767,039 SEC filing ↗

Source: SEC EDGAR (United States); every row links to where it was published. Event computed Sep 14, 2026.

Hunter C Smith sold 24,611 RHYTHM PHARMACEUTICALS, INC. (RYTM) shares for $2,370,778 on Aug 12, 2025

Large trade for this person

Flagged because this trade was large compared with this person’s own earlier open-market trades in the same currency — not because it is large in absolute terms. A trade that is routine for one insider can be flagged for another.

Hunter C Smith sold 24,611 RHYTHM PHARMACEUTICALS, INC. (RYTM) shares for $2,370,778 on Aug 12, 2025
Date Insider Transaction Shares Price Value Filing
Aug 12, 2025 Hunter C Smith S Open-market sale 24,611 held after: 116,915 $96.33 $2,370,778 SEC filing ↗

Source: SEC EDGAR (United States); every row links to where it was published. Event computed Sep 14, 2026.

Hunter C Smith sold 40,513 RHYTHM PHARMACEUTICALS, INC. (RYTM) shares for $3,267,278 on Jul 9, 2025

Large trade for this person

Flagged because this trade was large compared with this person’s own earlier open-market trades in the same currency — not because it is large in absolute terms. A trade that is routine for one insider can be flagged for another.

Hunter C Smith sold 40,513 RHYTHM PHARMACEUTICALS, INC. (RYTM) shares for $3,267,278 on Jul 9, 2025
Date Insider Transaction Shares Price Value Filing
Jul 9, 2025 Hunter C Smith S Open-market sale 17,113 held after: 141,922 $75.38 $1,289,978 SEC filing ↗
Jul 9, 2025 Hunter C Smith S Open-market sale 23,400 held after: 116,915 $84.50 $1,977,300 SEC filing ↗

Total of the rows above: $3,267,278, in the currency the filings report.

Source: SEC EDGAR (United States); every row links to where it was published. Event computed Sep 14, 2026.

Recent insider transactions

Of the 257 rows we hold, 0 are open-market purchases and 134 open-market sales (S) — the only codes we count as buying or selling.

The rest — awards, shares withheld to pay tax, option exercises, gifts and so on — follow from an employment contract or a transfer arranged off-market, not from a decision to buy or sell, so counting them would turn this into a pay table.

A price of 0.00 is a real reported figure on gifts (G) and share awards (A) — not a gap in our data.

Insider transactions disclosed to the SEC for RHYTHM PHARMACEUTICALS, INC., newest first, each with the filing behind it.
Date Insider Transaction Shares Price Value Filing
Aug 31, 2026 Hunter C Smith S Open-market sale 28,188 $106.20 $2.99M SEC filing ↗
Aug 31, 2026 Hunter C Smith S Open-market sale 11,514 $105.37 $1.21M SEC filing ↗
Aug 31, 2026 Hunter C Smith S Open-market sale 23,072 $104.59 $2.41M SEC filing ↗
Aug 31, 2026 Hunter C Smith M Option exercise or conversion 57,187 $25.79 $1.47M SEC filing ↗
Aug 13, 2026 Joseph Shulman S Open-market sale 5,079 $119.75 $608.2K SEC filing ↗
Aug 13, 2026 Joseph Shulman M Option exercise or conversion 2,024 $6.80 $13.8K SEC filing ↗
Aug 13, 2026 Jennifer Kayden Lee S Open-market sale 75,834 $117.38 $8.90M SEC filing ↗
Aug 13, 2026 Jennifer Kayden Lee M Option exercise or conversion 21,601 $6.80 $146.9K SEC filing ↗
Aug 13, 2026 Jennifer Kayden Lee M Option exercise or conversion 35,000 $24.29 $850.2K SEC filing ↗
Aug 12, 2026 Yann Mazabraud S Open-market sale 17,319 $117.47 $2.03M SEC filing ↗
Aug 12, 2026 Yann Mazabraud S Open-market sale 18,208 $116.49 $2.12M SEC filing ↗
Aug 12, 2026 Yann Mazabraud S Open-market sale 14,568 $115.43 $1.68M SEC filing ↗
Aug 12, 2026 Yann Mazabraud S Open-market sale 3,605 $114.70 $413.5K SEC filing ↗
Aug 12, 2026 Yann Mazabraud S Open-market sale 1,000 $112.86 $112.9K SEC filing ↗
Aug 12, 2026 Yann Mazabraud S Open-market sale 2,300 $111.80 $257.1K SEC filing ↗
Aug 12, 2026 Yann Mazabraud M Option exercise or conversion 46,625 $6.80 $317.1K SEC filing ↗
Jun 23, 2026 David W. J. McGirr M Option exercise or conversion 4,712 $0.00 $0 SEC filing ↗
Jun 23, 2026 Lynn A. Tetrault M Option exercise or conversion 4,712 $0.00 $0 SEC filing ↗
Jun 23, 2026 Stuart A Arbuckle M Option exercise or conversion 4,712 $0.00 $0 SEC filing ↗
Jun 23, 2026 Jennifer L. Good M Option exercise or conversion 4,712 $0.00 $0 SEC filing ↗
Jun 22, 2026 Lynn A. Tetrault S Open-market sale 37,000 $100.32 $3.71M SEC filing ↗
Jun 22, 2026 Lynn A. Tetrault M Option exercise or conversion 37,000 $28.27 $1.05M SEC filing ↗
May 18, 2026 Hunter C Smith M Option exercise or conversion 3,000 $17.87 $53.6K SEC filing ↗
Apr 1, 2026 Yann Mazabraud M Option exercise or conversion 12,875 $0.00 $0 SEC filing ↗
Mar 12, 2026 Edward T Mathers J Other acquisition or disposition 4,199 $0.00 $0 SEC filing ↗

From SEC Form 4 filings. Every row links to the filing it came from. How we calculate this.

What a Form 4 is

The report an officer, director or large shareholder must file after trading their own company’s stock.

Subsidiaries — 11 legal entities

Subsidiaries of RHYTHM PHARMACEUTICALS, INC.

11 legal entities named in the subsidiary exhibit filed with this company’s most recent 10-K. . Filing on SEC.gov.

This is not the full list. SEC rules only require a company to name its significant subsidiaries.

What that leaves out

Smaller entities are left out of the exhibit entirely. A short list here means a short exhibit — it does not mean the company owns nothing else. Nothing on this page is inferred: every name below is copied from the filing.

Subsidiaries RHYTHM PHARMACEUTICALS, INC. names in its most recent annual report, with the place each one is organised.
Subsidiary Organised in
Rhythm Pharma K.K. Japan
Rhythm Pharmaceuticals Canada Inc. Canada
Rhythm Pharmaceuticals France SAS France
Rhythm Pharmaceuticals Germany GmbH Germany
Rhythm Pharmaceuticals Italy S.r.l. Italy
Rhythm Pharmaceuticals Netherlands B.V. The Netherlands
Rhythm Pharmaceuticals Spain, SL Spain
Rhythm Pharmaceuticals Switzerland GmbH Switzerland
Rhythm Pharmaceuticals UK Limited United Kingdom
Rhythm Securities Corp. Massachusetts
Xinvento B.V. The Netherlands
What counts as a subsidiary

A subsidiary is a separate legal entity this company controls; it is not the same thing as a brand, a division or an office. These entities do not file with the SEC in their own right, so there is no separate page to open for them.

Think a number here is wrong? Open the linked filing and compare — how to report it.

Sources and technical notes

Every figure on this page comes from filings to the U.S. SEC via EDGAR. Nothing here is estimated, and nothing is taken from press coverage or company websites.

Share count: cover page of the latest filing (dei:EntityCommonStockSharesOutstanding), taken from RHYTHM PHARMACEUTICALS, INC.’s own filings and multiplied by our closing price. Full method.

What that share count means

the share count the company itself prints on the cover of its most recent filing, as of the date it signed that filing.

We do not take a market cap from a data vendor, and we do not estimate one: the figure is a share count from RHYTHM PHARMACEUTICALS, INC.’s own SEC filings multiplied by the closing price we hold for the same stock.